HIV prevention breakthrough? Twice-Yearly shot could replace daily pills

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Ability to understand and sign the Informed Consent Form, which must be obtained before the initiation of any study procedures, and willingness to comply with the protocol requirements Be a cisgender man, a non-binary person designated male at birth, or a transgender woman or transgender man Report having engaged in anal sex with a person designated male at birth within the last six months Be between 16 and 30 years of age Have a body weight equal to or greater than 35 kilograms Seek care at a participating study clinic for human immunodeficiency virus testing or initiation of human immunodeficiency virus pre-exposure prophylaxis, either spontaneously or through peer invitation Have a non-reactive result on a rapid test for human immunodeficiency virus Be an individual without prior use of human immunodeficiency virus pre-exposure prophylaxis, or an individual with prior use who remains in a situation of vulnerability, characterized by: a history of oral human immunodeficiency virus pre-exposure prophylaxis with at least two prior dispensations without return for a new pickup in the six months preceding the enrollment visit, or a history of long-acting cabotegravir use with a delay of at least one scheduled reload dose Exclusion Criteria: Known hypersensitivity to the study medication, its metabolites, or formulation excipients Severe hepatic impairment or a history or current clinical condition of decompensated liver cirrhosis, such as ascites, encephalopathy, or variceal bleeding Known or suspected severe active infection, such as active tuberculosis Need for continuous use of contraindicated concomitant medications Any clinical or psychosocial condition, or prior treatment, that in the opinion of the investigator makes the participant unsuitable for the study or unable to comply with dosing requirements Confirmed or suspected infection with the human immunodeficiency virus Plans to move outside the study area during the follow-up period Prior participation in a clinical study using Lenacapavir in the PURPOSE study Prior participation in a human immunodeficiency virus vaccine study, except in cases where the participant provides documentation demonstrating receipt of placebo and not the active product Current participation in another interventional human immunodeficiency virus prevention study that, in the opinion of the investigator, may interfere with the conduct of this study